Evidence map›Paper›PMID 42618875›Full record

ArticleInternational journal of hematology2026

Voriconazole versus itraconazole for antifungal prophylaxis in patients with graft-versus-host disease: A prospective randomized trial.

Yoshiki Hayashi, Yoshinobu Kanda, Hirohisa Nakamae, Masatsugu Tanaka, Noriko Doki, Michihiro Hidaka, Shingo Yano, Kazuo Hatanaka, Akio Kohno, Yukiyoshi Moriuchi and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yoshiki HayashiDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Noriko DokiDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Michihiro HidakaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Shingo YanoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kazuo HatanakaDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Akio KohnoDepartment of Hematology and Oncology, JA Aichi Konan Kosei Hospital, Konan, Japan.
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Toshio WakayamaDepartment of Hematology and Oncology, Shimane Prefectural Central Hospital, Izumo, Shimane, Japan.
Takuya YamashitaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Tohru TakataDepartment of Infection Control, Fukuoka University Hospital, Fukuoka, Japan.
Minoru YoshidaFourth Department of Internal Medicine, Teikyo University School of Medicine, Kawasaki, Japan.
Masayuki HinoDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. tafukuda@ncc.go.jp.ORCID http://orcid.org/0009-0006-9490-4669

Funding

National Cancer Research and Development Fund 23-A-15
6 · The paper itself

Abstract

Graft-versus-host disease (GVHD) increases the risk of invasive fungal infection (IFI) after allogeneic hematopoietic cell transplantation (HCT). This randomized phase II selection trial evaluated protocol-defined prophylaxis success and safety of voriconazole (VRCZ) and itraconazole (ITCZ) prophylaxis in patients with GVHD.Allogeneic HCT recipients with grade II-IV acute GVHD or chronic GVHD requiring systemic corticosteroids were randomized to receive VRCZ or ITCZ for 60 days. Success was defined as survival without protocol-defined proven/probable IFI through day 60 and receipt of study drug for at least 48 days.Sixty-six patients (33 per group) were randomized. The success rate was 88% with VRCZ and 94% with ITCZ (difference,  - 6.1 percentage points; 95% confidence interval,  - 20.0 to 7.7); ITCZ was selected by the prespecified rule. No protocol-defined IFI occurred with VRCZ; one probable and one possible IFI occurred with ITCZ. Post hoc reclassification using 2008 consensus criteria yielded no IFI, whereas 2020 updated criteria yielded possible IFI in one VRCZ and two ITCZ patients. Grade 3/4 adverse events occurred in 27% and 21%, respectively.In conclusion, both regimens achieved high protocol-defined prophylaxis success. The study was not powered to establish comparative antifungal efficacy; results mainly inform feasibility of azole prophylaxis in GVHD.

Indexed as

Antifungal prophylaxisAzolesGraft-versus-host diseaseInvasive fungal infectionStem cell transplantation

Identifiers

PMID42618875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.